Department of Cardiovascular, Neural and Metabolic Sciences, Faint & Fall Programme, IRCCS Istituto Auxologico Italiano, Ospedale San Luca, Piazzale Brescia 20, Milano 20149, Italy.
Department of Cardiology, Arrhythmology Centre and Syncope Unit, Ospedali del Tigullio, via don Bobbio 24, 16033 Lavagna, Italy.
Eur Heart J. 2021 Feb 1;42(5):508-516. doi: 10.1093/eurheartj/ehaa936.
The benefit of cardiac pacing in patients with severe recurrent reflex syncope and asystole induced by tilt testing has not been established. The usefulness of tilt-table test to select candidates for cardiac pacing is controversial.
We randomly assigned patients aged 40 years or older who had at least two episodes of unpredictable severe reflex syncope during the last year and a tilt-induced syncope with an asystolic pause longer than 3 s, to receive either an active (pacing ON; 63 patients) or an inactive (pacing OFF; 64 patients) dual-chamber pacemaker with closed loop stimulation (CLS). The primary endpoint was the time to first recurrence of syncope. Patients and independent outcome assessors were blinded to the assigned treatment. After a median follow-up of 11.2 months, syncope occurred in significantly fewer patients in the pacing group than in the control group [10 (16%) vs. 34 (53%); hazard ratio, 0.23; P = 0.00005]. The estimated syncope recurrence rate at 1 year was 19% (pacing) and 53% (control) and at 2 years, 22% (pacing) and 68% (control). A combined endpoint of syncope or presyncope occurred in significantly fewer patients in the pacing group [23 (37%) vs. 40 (63%); hazard ratio, 0.44; P = 0.002]. Minor device-related adverse events were reported in five patients (4%).
In patients aged 40 years or older, affected by severe recurrent reflex syncope and tilt-induced asystole, dual-chamber pacemaker with CLS is highly effective in reducing the recurrences of syncope. Our findings support the inclusion of tilt testing as a useful method to select candidates for cardiac pacing.
ClinicalTrials.gov identifier NCT02324920, Eudamed number CIV-05-013546.
心脏起搏在因倾斜试验引起的严重复发性反射性晕厥和停搏的患者中的益处尚未确定。倾斜试验选择心脏起搏候选者的有用性存在争议。
我们随机分配了年龄在 40 岁或以上的患者,这些患者在过去一年中至少有两次不可预测的严重反射性晕厥发作,并且倾斜诱导的晕厥伴有长于 3 秒的停搏,他们接受了主动(起搏开启;63 例)或被动(起搏关闭;64 例)双腔起搏器闭环刺激(CLS)。主要终点是首次晕厥复发的时间。患者和独立结果评估者对所分配的治疗均不知情。在中位随访 11.2 个月后,起搏组的晕厥患者明显少于对照组[10(16%)对 34(53%);风险比,0.23;P=0.00005]。1 年时的估计晕厥复发率为 19%(起搏)和 53%(对照),2 年时为 22%(起搏)和 68%(对照)。起搏组发生晕厥或先兆晕厥的复合终点患者明显少于对照组[23(37%)对 40(63%);风险比,0.44;P=0.002]。有 5 例(4%)患者报告了轻微的设备相关不良事件。
在年龄为 40 岁或以上的患有严重复发性反射性晕厥和倾斜诱导性停搏的患者中,具有 CLS 的双腔起搏器可有效减少晕厥的复发。我们的研究结果支持将倾斜试验作为选择心脏起搏候选者的一种有用方法。
ClinicalTrials.gov 标识符 NCT02324920,Eudamed 编号 CIV-05-013546。